Is Fosamax Safe During Pregnancy? Alendronate Risks, Data, and What to Do Instead

The Short Answer: Alendronate and Pregnancy Do Not Mix

Stop alendronate before you try to conceive. That is the clearest clinical take from the available evidence. The FDA prescribing information for alendronate states directly that the drug may cause fetal harm when administered to a pregnant woman, and it advises clinicians to inform patients of this potential risk. Because bisphosphonates bind tightly to bone mineral, alendronate does not simply clear from your body when you stop the pill. It can remain in your skeleton for years, which means pregnancy planning requires a conversation with your prescriber well in advance of conception, not the day you see a positive test.

This article covers what the animal data show, what sparse human evidence exists, why the long half-life in bone matters for women of reproductive age, what happens at the breast, and what evidence-based alternatives exist at every life stage.

Why Alendronate Is Prescribed and Who Gets It

Alendronate inhibits osteoclast-mediated bone resorption. It is approved by the FDA for the prevention and treatment of osteoporosis in postmenopausal women, treatment of osteoporosis in men, glucocorticoid-induced osteoporosis in both sexes, and Paget's disease of bone.

Women of Reproductive Age Who May Be Prescribed It

Most prescriptions go to postmenopausal women, where the risk-benefit calculation looks very different than in a 30-year-old. Younger women who may still be prescribed bisphosphonates include those with:

• Premenopausal osteoporosis (idiopathic or secondary to conditions like anorexia nervosa, celiac disease, or long-term glucocorticoid use)
• PCOS with low bone density, which can occur in lean women with hypothalamic dysfunction
• Osteogenesis imperfecta or other heritable bone disorders
• Glucocorticoid-induced osteoporosis from long-term treatment of lupus, inflammatory bowel disease, or other autoimmune conditions common in women

ACOG Practice Bulletin guidance on osteoporosis recommends that women of reproductive age with low bone density be counseled explicitly about bisphosphonate teratogenicity and contraception requirements before starting therapy. The number of reproductive-age women on these drugs is small but not negligible, and the conversation about family planning is often skipped.

Perimenopause and Postmenopause

For the typical postmenopausal woman, pregnancy is not a concern. But perimenopause is a gray zone. Ovulation can still occur in the early perimenopausal years, and accidental pregnancy, while rare after age 45, does happen. Any woman who has not had 12 consecutive months without a period should be counseled that alendronate is contraindicated in pregnancy.

What the Animal Data Show

Animal studies provide the most direct evidence of fetal harm, and the results are concerning.

In rat studies, doses of alendronate equivalent to 0.26 times the human dose produced maternal hypocalcemia and perinatal mortality in offspring. At higher doses, pups showed delayed ossification, reduced bone length, and skeletal abnormalities. Rabbits given alendronate at doses equivalent to 10 times the human dose showed incomplete fetal ossification. These findings are consistent with bisphosphonate pharmacology: the drug disrupts normal calcium metabolism and bone turnover, and a developing fetus depends on tightly regulated calcium flux for skeletal formation.

The FDA label states clearly: "Bisphosphonates are incorporated into the bone matrix, from which they are gradually released over periods of weeks to years." That slow release means that even if you stop alendronate before conception, residual drug stored in bone may still be mobilized during pregnancy, when normal physiologic bone resorption increases to supply calcium to the growing fetus.

Human Pregnancy Data: What We Actually Know (and What We Don't)

The honest answer is that human data are very thin. Women of reproductive age have historically been excluded from clinical trials, and alendronate trials were designed almost entirely around postmenopausal populations. This is an area where the evidence gap is real and clinicians are working largely from case reports, case series, and extrapolation from animal findings.

Published Case Reports and Small Series

A 2018 review published in Osteoporosis International identified 78 cases in the published literature of bisphosphonate exposure during pregnancy, most of them inadvertent (the woman became pregnant while on therapy). The majority of reported pregnancies resulted in live births, and most infants appeared healthy at birth. Reassuringly, no consistent pattern of major structural malformations has emerged in case reports.

But this finding requires careful interpretation. Case reports skew toward normal outcomes because adverse outcomes are more likely to go unreported or be attributed to other causes. The total number of known exposures is far too small to rule out a risk that affects, say, 1 in 200 pregnancies. Pediatric follow-up in these cases was often brief, and subtle effects on infant bone metabolism might not be apparent in early infancy.

Placental Transfer and Fetal Bone Accumulation

Bisphosphonates cross the human placenta. A 2011 case report in the Journal of Clinical Endocrinology and Metabolism documented measurable alendronate levels in fetal bone obtained at delivery after inadvertent first-trimester exposure, confirming that the drug does reach the fetal skeleton. The fetal bone concentration was lower than maternal bone concentration, but the drug was present. Because fetal bone is more metabolically active than adult bone during development, the biological significance of even low concentrations is unknown.

What the FDA Label Says Directly

The FDA-approved alendronate prescribing information states: "There are no adequate and well-controlled studies in pregnant women. Alendronate should be used during pregnancy only if the potential benefit justifies the potential risk to the mother and fetus." In practice, clinicians across maternal-fetal medicine and endocrinology interpret this as a contraindication in nearly all circumstances. There is no recognized clinical scenario in which alendronate's bone benefit to a pregnant woman would outweigh the potential fetal risk, because safer supportive measures exist.

The Long Half-Life Problem: Planning for Pregnancy While on Alendronate

This is where alendronate differs meaningfully from most drugs. Stopping a pill the day you see a positive test is not sufficient.

Alendronate's terminal half-life in bone is estimated at more than 10 years. The drug is released slowly from bone as normal bone remodeling occurs. During pregnancy, the physiologic increase in bone resorption (to meet fetal calcium demands) accelerates this release. The result is that a woman who stopped alendronate 12 months before conception may still have measurable bisphosphonate being released from her skeleton throughout pregnancy.

How Long Should You Stop Before Trying to Conceive?

No randomized trial has defined an optimal washout period, because such a trial would be unethical. Expert guidance, including recommendations from ACOG and published opinion pieces in the American Journal of Obstetrics and Gynecology, generally suggests stopping bisphosphonate therapy at least one to two years before a planned pregnancy. Some specialists recommend an even longer pause, up to five years, depending on how long the woman was on therapy.

The clinical reasoning: the longer a woman has taken alendronate, the greater her skeletal burden of the drug, and the longer the anticipated release continues after stopping. A woman who took alendronate for three years has a larger bone reservoir than someone who took one year of preventive therapy.

The Bone Loss Question

Women often worry: if I stop alendronate to plan a pregnancy, will I lose the bone density I gained? This is a reasonable concern. Studies show that bone mineral density (BMD) gains from bisphosphonate therapy are partly retained for several years after stopping, particularly at the spine and hip. This "residual effect" is one reason drug holidays are considered safe for postmenopausal women with moderate risk. For a young woman stopping to conceive, the residual effect offers some protection, but she should have BMD re-evaluated in the postpartum period.

Pregnancy-Associated Osteoporosis: A Separate Condition Entirely

Some women develop osteoporosis for the first time during pregnancy or the postpartum period. This is called pregnancy-associated osteoporosis (PAO) or transient osteoporosis of pregnancy. It is rare, affecting roughly 1 in 1,000,000 pregnancies, and typically presents as severe low back pain or fragility fractures (usually vertebral) in the third trimester or early postpartum.

Why Alendronate Is Not the Treatment During Active Pregnancy

In the context of PAO, alendronate is not appropriate during the pregnancy itself. The standard approach during pregnancy is calcium and vitamin D supplementation, rest, and pain management. After delivery and once breastfeeding has concluded, bisphosphonates may be considered if BMD is severely reduced and the woman does not plan another immediate pregnancy.

Teriparatide (Forteo) has been used off-label in some postpartum PAO cases with severe fractures, but it also carries a pregnancy contraindication and requires the same planning discussions.

Fosamax and Breastfeeding: What the Evidence Says

Breast Milk Transfer

Human data on alendronate transfer into breast milk are essentially nonexistent. The NIH LactMed database notes that no published information is available on the use of alendronate during breastfeeding, and that because bisphosphonates bind avidly to calcium in bone, excretion into calcium-rich breast milk is biologically plausible, though the extent in humans is not established.

Oral Bioavailability in Infants

There is one partial reassurance: alendronate has very poor oral bioavailability even in adults (roughly 0.64% under fasting conditions). If an infant were exposed through breast milk, the amount actually absorbed in the infant's gut would likely be small. But "likely small" and "proven safe" are not the same thing, and no studies have examined infant bone turnover markers or BMD in infants of mothers who continued bisphosphonates postpartum.

Clinical Recommendation

LactMed states that because of the lack of data and the theoretical concern about interference with infant bone development, avoidance of alendronate during breastfeeding is the conservative standard. If a woman with very high fracture risk absolutely needs bisphosphonate therapy in the postpartum period, she and her care team should discuss whether to delay therapy until weaning or to supplement with formula and stop breastfeeding.

Who This Drug Is Right For and Not Right For, by Life Stage

Reproductive Years (Ages 18-40, Not Actively TTC)

Alendronate may be appropriate for a premenopausal woman with documented low BMD and high fracture risk when safer alternatives have failed, provided:

• She is using reliable contraception (hormonal or barrier)
• She has been counseled explicitly about the need to stop well before any planned pregnancy
• The prescriber has documented this discussion in the chart
• She is monitored with DXA every one to two years

Trying to Conceive

Alendronate is not appropriate during active conception attempts. The prescriber should taper or stop the medication and build a bridge plan using calcium, vitamin D, weight-bearing exercise, and fall prevention.

Pregnancy

Alendronate is contraindicated. Full stop. No clinical benefit in the pregnant woman justifies the unknown fetal risk. If a woman discovers she is pregnant while taking alendronate, she should stop immediately and notify her OB-GYN and any prescribing specialist. The pregnancy does not need to be terminated on this basis alone, given the limited human data suggesting most inadvertent exposures do not result in apparent fetal harm, but the situation warrants close monitoring and specialist involvement.

Postpartum and Lactation

Not recommended during breastfeeding. If bone loss is a serious concern postpartum (as in PAO cases), the clinical team should individualize the decision about timing of therapy relative to weaning.

Perimenopause

Ovulation may still occur. Use contraception until menopause is confirmed (12 consecutive months without a period, typically after age 51 in US women). Bisphosphonate therapy can begin or continue with the same contraception caveat.

Postmenopause

The standard, well-supported indication. Pregnancy risk is not relevant, though women should still be aware of other contraindications (esophageal disorders, inability to sit upright 30 minutes after dosing, hypocalcemia).

Safe Bone-Health Alternatives During Pregnancy and Lactation

You do not have to accept bone loss passively while pregnant or nursing. Evidence-based strategies that are safe in pregnancy include:

Calcium and Vitamin D

The Institute of Medicine recommends 1,000 mg of elemental calcium per day for pregnant and lactating women ages 19 to 50, with 600 IU of vitamin D3 daily. Calcium carbonate is cheapest but requires stomach acid; calcium citrate is better absorbed without food and preferred if you have GERD or take antacids.

Weight-Bearing Exercise

A systematic review in the Journal of Bone and Mineral Research found that resistance training and weight-bearing aerobic exercise maintain or improve BMD in premenopausal women. Walking, low-impact aerobics, and prenatal yoga all provide skeletal loading without fetal risk.

Nutrition

Adequate protein intake supports bone matrix formation. Aim for at least 1.1 g/kg of body weight daily in pregnancy, per ACOG nutritional guidance. Vitamin K2 (from leafy greens and fermented foods) supports osteocalcin carboxylation, though supplemental K2 data in pregnancy are limited.

Monitoring

Women with known low BMD who become pregnant should have a baseline DXA scan postpartum (not during pregnancy, due to radiation exposure) and vitamin D levels checked each trimester. Severe deficiency (25-OH vitamin D <20 ng/mL) should be treated with higher-dose supplementation under clinician guidance.

Conditions That Intersect with Bone Health in Women

PCOS

Women with PCOS who are lean or have hypothalamic dysfunction may have lower BMD than expected. Estrogen deficiency from irregular ovulation drives bone loss. A 2016 meta-analysis in Clinical Endocrinology found that lean women with PCOS had significantly lower BMD than BMI-matched controls. If these women are prescribed bisphosphonates, the contraception and pregnancy planning discussion is mandatory.

Endometriosis and Hormonal Suppression

GnRH agonist therapy (leuprolide) used to manage endometriosis causes a medically induced hypoestrogenic state that can produce rapid bone loss. Bisphosphonates are sometimes prescribed as add-back therapy for bone protection. Women on this combination who want to conceive face a compound planning challenge: stopping the GnRH agonist, managing endometriosis, and timing bisphosphonate cessation.

Glucocorticoid-Induced Osteoporosis

Women with autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) requiring long-term prednisone are at high risk for rapid bone loss and may be prescribed bisphosphonates at a younger age. ACR guidelines recommend bisphosphonate therapy for women on prednisone ≥5 mg/day for ≥3 months with moderate-to-high fracture risk. These women are often in their reproductive years, and family planning conversations must be part of the rheumatology and OB-GYN visits.

Evidence Gaps: What We Still Don't Know

Women have been systematically underrepresented in bisphosphonate trials. The landmark Fracture Intervention Trial (FIT) that established alendronate's efficacy enrolled only postmenopausal women with low BMD, a population with no pregnancy risk. All the reproductive-age data come from case reports, registry data, and pharmacokinetic extrapolation.

Specific unknowns include:

• The dose of alendronate in breast milk and the amount absorbed by nursing infants
• Whether fetal bisphosphonate accumulation produces any measurable effect on infant bone health at 2, 5, or 10 years of age
• The optimal washout period before conception that minimizes fetal exposure from bone-stored drug
• Whether short-duration premenopausal alendronate therapy (1-2 years) carries a lower pregnancy risk than long-duration therapy (>5 years)

This honesty about unknowns is not a reason to panic. It is a reason to plan carefully and to see a specialist who can individualize the risk-benefit analysis for your specific bone health history and family planning goals.

What to Tell Your Doctor

If you are on alendronate and thinking about pregnancy, bring these specific questions to your next appointment:

1. How long have I been on this drug, and what is my estimated skeletal drug burden?
2. How far in advance should I stop before trying to conceive, given my fracture history and current BMD?
3. What is my T-score now, and how much bone loss can I safely tolerate during a planned drug pause?
4. What calcium, vitamin D, and lifestyle measures will you recommend as a bridge?
5. If I become pregnant while still on alendronate, who should I call first, and what monitoring should my baby have?

A maternal-fetal medicine specialist, a reproductive endocrinologist, or an endocrinologist with experience in premenopausal bone disease is your best resource if your OB-GYN has limited experience with this specific overlap.